The cloud based platform will facilitate Endocyte to support its multiple ongoing clinical studies, designed for the development of targeted therapies for cancer and other serious diseases.

Endocyte is using Medidata Rave to ensure high quality and integrity of captured patient data, while Medidata CTMS to streamline operations.

Medidata Solutions president Glen de Vries said the the company’s clinical cloud solutions accelerate trials, while reducing both cost and risk.

"Embracing Medidata’s platform will bring continued efficiency to the development of Endocyte’s rich pipeline," Vries added.